H2020Индивидуална стипендия2021–2023

FIBCOLIT · Modulation of intestinal barrier function and inflammation via butyrate-promoting dietary fibre

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2021-09-01 → 2023-08-31
Финансиране от ЕС: 203 852 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Диетичните фибри, които стимулират производството на бутират, се изследват за влиянието им върху чревната флора и възпаленията при пациенти с микроскопичен колит. Това помага да се разбере как храната може да укрепи чревната бариера и да облекчи симптомите без лекарства.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Modulation of intestinal barrier function and inflammation via butyrate-promoting dietary fibre

Intestinal barrier function refers to the intestinal epithelium’s task of restricting the passage of noxious substances into circulation. Anomalies in the mechanisms that uphold intestinal barrier function can lead to increased passage of luminal molecules into circulation. This increase in intestinal permeability to bacterial antigens can subsequently activate pro-inflammatory signalling. Increased intestinal permeability is frequently observed in patients with disorders characterised by intestinal inflammation, such as inflammatory bowel diseases (IBDs, Crohn’s disease and ulcerative colitis) and microscopic colitis (MC). Although dietary fibres have shown promise in alleviating the symptoms of IBD, the underlying biological mechanisms remain elusive. One such mechanism could be certain dietary fibres’ capability to modify the composition and functionality of intestinal microbiota by promoting the growth of butyrate-producing bacteria. Indeed, studies have shown that IBD and MC patients display decreased abundance of butyrate-producing bacteria. Butyrate is the main energy source for colonocytes, but it also regulates cell proliferation and gene expression, strengthens intestinal barrier function, and induces anti-inflammatory signalling. Thus, increasing luminal butyrate availability via butyrate-promoting dietary fibre potentially provides a non-pharmaceutical option to restore intestinal homeostasis in certain diseases. The overall aim of this study is to examine whether and how a 6-week intervention with a dietary fibre known to promote luminal butyrate production affects measures intestinal barrier function, intestinal inflammation, intestinal microbiota, and gastrointestinal symptoms in MC patients. This objective has considerable importance given that 1) the last 20 years have seen a significant global increase in the incidence and prevalence of inflammatory bowel diseases (IBD) , and 2) intestinal inflammation, even at a low grade, drives the development of systemic inflammation in obesity and obesity-related disorders, such as metabolic syndrome and type 2 diabetes. Considering the personal, societal, and economic burden of these diseases, there is a growing need for a better understanding of the physiological mechanisms that maintain and modulate intestinal homeostasis. Should DF supplementation prove effective at restoring intestinal homeostasis in MC, it could potentially offer a non-pharmaceutical option to disease prevention and management as well as reveal new insights about the pathophysiological mechanisms that promote intestinal inflammation.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The FIBCOLIT project investigates the impact of fermentable dietary fibres (DFs) on intestinal physiology and inflammation via dietary intervention study in human patients with microscopic colitis (MC), a chronic disease characterised by sustained mild intestinal inflammation. This subject topic has significant interest for public health considering 1) the increased global incidence and prevalence of inflammatory bowel diseases in the last 20 years, and 2) the increased scientific knowledge regarding the role of intestinal inflammation in driving the development of systemic inflammation in metabolic diseases. Currently, considerable knowledge gaps exists regarding the biological and physiological mechanisms that maintain and modulate intestinal homeostasis as well as the pathophysiological mechanisms that lead to chronic intestinal inflammation. The FIBCOLIT project aims to answer these open scientific questions through a multi-omics approach employing several analytical methods to examine DF-induced changes in intestinal barrier function, inflammatory markers, intestinal microbiota composition and functionality, as well as gastrointestinal symptoms, quality of life, and general well-being. The projects utilises a DF known to promote the production of luminal butyrate, a short-chain fatty acid that has been associated with several positive health effects. Overall, the project's methodology allows specific targeting of the mechanistic links between DF intake, butyrate, and intestinal health. Should DF supplementation prove effective at restoring intestinal homeostasis, it could potentially offer a non-pharmaceutical option to the prevention and management of diseases characterised by chronic intestinal inflammation. The project results could potentially also serve as starting point in the development of functional foods for the general public.

Оригинален текст от CORDIS (на английски).

Участници

OREBRO UNIVERSITY · OrebroКоординаторШвеция